Replimune Group Inc. (REPL) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 95% of 52W Range • RSI-14 at 75.1 (OVERBOUGHT (>70))
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While REPL currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.58) and Max Pain ($18.26) forces dealer call-delta covering toward $19.41.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Replimune Group Inc. (REPL) surged +8.28% to $17.39, trading at 95% of its 52-week range ($1.5 – $18.27). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Key TakeawaysReplimune shares jumped 17% after more than 15 institutions prescribed TUDRIQEV in its first three weeks. The uptake suggests doctors will make room for a therapy injected into tumors.
Leerink Partners analyst Daina Graybosch maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $19 to $31.
Investors responded positively to stronger financial performance and progress in medical research.
Replimune Group (REPL) shares moved after the company posted second quarter results, showing a reduced net loss of US$57.12 million, down from US$83.1 million for the same period a year earlier. The latest move comes aft
Manufacturing control and payer coverage alignment could determine whether early traction translates into sustained revenue growth.
Moby summary of Replimune Group, Inc.'s Q2 2027 earnings call
TUDRIQEV launched with $450,000 price tag and early traction across oncology institutions.
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDTCompany ParticipantsArleen GoldenbergSushil Patel - CEO &...
TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWI
Replimune Group (NASDAQ:REPL) reported second-quarter financial results on Wednesday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on REPL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for REPL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Replimune Group Inc. (REPL) ranks #442 by composite RQD confidence (46/100, grade D) and #294 by equity capitalization ($1.65B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with REPL at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| REPL
ACTIVE
Replimune Group Inc. | D | 46/100 | — | — | -35.0% | +8.28% | $1.65B | Benchmark Subject |
| IMCR Immunocore Holdings plc | E | 31/100 | — | 96.0% | -35.0% | -4.11% | $1.61B | /imcr-vs-repl → |
| NVAX Novavax Inc. | D+ | 56/100 | 3.9x | 93.5% | 85.0% | +1.45% | $1.73B | /nvax-vs-repl → |
| MAZE Maze Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +0.63% | $1.77B | /maze-vs-repl → |
| LYCA Lycia Therapeutics Inc. | C- | 59/100 | — | — | — | +10.70% | $1.44B | /lyca-vs-repl → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), Replimune Group Inc. (REPL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$313.9M, operating cash flow of -$280.3M, and free cash flow of -$280.3M (-45.8% YoY). On the balance sheet, REPL closed FY2025 with $333.6M in total assets against $47.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $0 | -$313.9M | -$280.3M | -$280.3M | $333.6M | $47.6M |
| FY2024 (FY) | 2025-03-31 | $0 | -$247.3M | -$192.3M | -$192.3M | $603.6M | $46.0M |
| FY2023 (FY) | 2024-03-31 | $0 | -$215.8M | -$185.5M | -$185.5M | — | — |
As of 2026-11-01, Replimune Group Inc. (NASDAQ: REPL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $17.39 (+8.28% 1D, market cap $1.65B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, REPL ranks #442 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), REPL carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMCR (Immunocore Holdings plc) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B) and NVAX (Novavax Inc.) posts a D+ grade (56/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.73B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
Per REPL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001737953), Replimune Group Inc. generated $0 in revenue, -$313.9M in net income, and -$280.3M in free cash flow against $333.6M in total assets and $47.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
REPL last traded at $17.39 (+8.28% on volume of 5,146,201 shares), positioning the stock +28.06% above its 50-day simple moving average ($13.58) and +87.19% above its 200-day simple moving average ($9.29). Across its 52-week range of $1.50 to $18.27, REPL sits at the 94.8% percentile with a 14-day RSI of 75.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($15.22 to $19.56).
Why REPL Stock surged +8.28% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.